Pathology of systemic lupus erythematosus: The challenges ahead

Methods in Molecular Biology

Volumn 1134, Issue , 2014, Pages 1-16

  Azevedo, Pedro Correia ^a   Murphy, Grainne ^b   Isenberg, David A ^c  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmunity; Cellular and humoral mechanisms; Genetics; Immunology; Organ damage; Pathology; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; FAS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INTERFERON; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL POPULATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; ENVIRONMENTAL FACTOR; ESTROGEN METABOLISM; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NULL ALLELE; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRANSCRIPTION REGULATION; ULTRAVIOLET RADIATION;

AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HORMONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 84896309112     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0326-9_1     Document Type: Article

References (91)

1. Lu LJ, Wallace DJ, Ishimori ML, Scofi eld RH, Weisman MH (2010) Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 19:119-129
2. Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and county of birth. Arthritis Rheum 38:551-558
3. Gladman DD, Urowitz MB (2007) Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois' Lupus erythematosus, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1333-1353
4. Sullivan KE (2000) Genetic of systemic lupus erythematosus: clinical implications. Rheum Dis Clin North AM 26:229-256
5. Walport MJ (2002) Complement and systemic lupus erythematosus. Arthritis Res 4(Suppl 3): S279-S293
6. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B et al (2007) Gene copynumber variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Geneti 80:1037-1054
7. Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E et al (2007) Specifi c combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet 15:823-830
8. Rahman A, Isenberg D (2008) Systemic lupus erythematosus. N Eng J Med 358:929-939
9. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifi es susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204-210
10. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550-555
11. Sigurdsson S, Nordmark G, Goring HHH, Lindroos K, Wiman AC, Sturfelt G et al (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5genes are associated with systemic lupus erythematosus. Am J Hum Gen 76:528-537
12. Stern R, Fishman J, Brusman H, Kunkel HG (1977) Systemic lupus erythematosus associated with Klinefelter's syndrome. Arthritis Rheum 20:18-22
13. Chanchoub G, Uz E, Maalej A (2009) Analysis of skewed X chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases. Arthritis Res Ther 11:R106
14. Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 40:1725
15. Cutolo M, Pizzorni C, Sulli A (2011) Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 11:84-87
16. Patel D, Richardson B (2013) Drug-induced lupus: etiology, pathogenesis, and clinical aspects. In: Wallace DJ, Hahn BH (eds) Dubois' Lupus erythematosus, 8th edn. Elsevier, Philadelphia, pp 484-494
17. James JA, Kaufman KM, Farris AD, Taylor- Albert E, Lehman TJ, Harley JB (1997) An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100:3019-3026
18. Netea MG, van der Meer JWH (2001) Mechanisms of disease - immunodefi ciency and genetic defects of pattern-recognition receptors. N Eng J Med 364:60-70
19. Ronnblom LE, Alm GV, Oberg KE (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid-tumors. Ann Intern Med 115:178-183
20. Lahita RG, Bradlow HL, Kunkel HG, Fishman J (1979) Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 22:1195-1198
21. Fromer JL (1950) The use of testosterone in chronic lupus erythematosus. Preliminary report. Lahey Clin Bul 8:13-17
22. Agnello V, Pariser K, Gell J, Gelfand J, Turksoy RN (1983) Preliminary observations on danazol therapy of systemic lupus erythematosus. Effects on DNA antibodies, thrombocytopaenia and complement. J Rheum 10:682-687
23. Zen M, Ghiradello A, Iaccarino L, Tonon M, Campana C, Arienti S et al (2010) Hormones, immune response and pregnancy in healthy women and pregnancy. Swiss Med Weekly 140:187-201
24. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B (2006) Sex hormones and SLE: infl uencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 305: 67-88
25. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B (2002) Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 109:1625-1633
26. Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL (2008) 17 beta-oestradiol alters the activity of conventional and IFNproducing killer dendritic cells. J Immunol 180:1423-1431
27. Hiran T (1998) IL-6 and its receptor. Int Rev Immunol 6:249-284
28. Tackey E, Lipsky P, Illei G (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13:339-343
29. Linker-Israeli M, Deans R, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 147:117-123
30. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY (2000) Increased excretions of 2-microglobulin, IL-6 and IL-8 and decreased excretion of Tamm- Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85:207-214
31. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H (2009) Accuracy of cerebrospinal fl uid IL-6 testing for diagnosis of lupus psychosis. A multicentre retrospective study. Clin Rheumatol 28:1319-1323
32. Herrera-Esparza R, Barbosa-Cisneros R, Villalobos-Hurtado R, Avalos-Diaz E (1998) Renal expression of IL-6 and TNF-? genes in lupus nephritis. Lupus 7:154-158
33. Mihara M, Takagi N, Takeda Y, Ohsugi Y (1998) IL-6 receptor blockade inhibits the onset of autoimmune kidney disease in NZB/ Wf1 mice. Clin Exp Immunol 112:397-402
34. Illei G, Yarboro C, Shirota Y, Daruwalla J, Tackey E, Takada K et al (2006) Tocilizumab (humanized anti-IL6 receptor antibody) in patients with systemic lupus erythematosus(SLE): safety, tolerability and preliminary effi cacy. Arthritis Rheum 54:4043
35. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J et al (1995) Role of Interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839-844
36. Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH et al (2003) Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 42:935-938
37. Ronnelid J, Tejde A, Mathsson L, Nilsson- Ekdahl K, Nilsson B (2003) Immune complexes from SLE sera induce IL-10 production from normal peripheral blood mononuclear cells by an Fc?RII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 62:37-42
38. Sun KH, Yu CL, Tang SJ, Sun GH (2000) Monoclonal anti-double stranded DNA autoantibody stimulates the expression of IL-1?, IL-6, IL-8, IL-10 and TNF-? from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 99:352-360
39. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH et al (2000) Clinical and biologic effects of antiinterleukin- 10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1800
40. Bengtsson G, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H et al (2000) Activation of type 1 Interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9:664-671
41. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100:2610-2615
42. Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431-1442
43. Fitzgerald-Bocarsly P, Dai J, Singh S (2008) Plasmacytoid dendritic cells and type 1 IFN: 50 years of convergent history. Cytokine Growth Factor Rev 19:3-19
44. Lovgren T, Eloranta ML, Bave U, Alm GV, Rönnblom L (2004) Induction of interferon-? production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50:1861-1872
45. Baccala R, Hoebe K, Kono DH, Beutler B, Theofi lopoulos N (2007) TLR-dependent and TLR-independent pathways of Type 1 interferon induction in systemic autoimmunity. Nat Med 13:543-551
46. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U et al (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type 1 IFN. J Immunol 176:2074-2078
47. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley B, Crow MK (2008) Association of the IRF5 risk haplotype with high serum interferon-? activity in systemic lupus erythematosus patients. Arthritis Rheum 58:2481-2487
48. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977-986
49. Hin Yap D, Neng Lai K (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed 2010:365083. doi: 10.1155/2010/ 365083. Epub 2010 May 6
50. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th-17 mediated infl ammation in auto-immunity. Clin Immunol 127:385-393
51. Zhang Z, Kyttaris VC, Tsokos GC (2009) The role of IL-23/IL-17 axis in lupus nephritis. Journal Immunol 183:3160-3169
52. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE et al (2008) Expanded double-negative T cells in patients with systemic lupus erythematosus produce IL-17 and infi ltrate the kidneys. Journal Immunol 181:8761-8766
53. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:491-502
54. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS et al (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198-204
55. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P et al (2001) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 293:2111-2114
56. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum 44:1313-1319
57. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Effi cacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721-731
58. Jacob CO, Mcdevitt HO (1988) Tumour necrosis factor-alpha in murine autoimmune lupus nephritis. Nature 331:356-358
59. Mohan AK, Edwards ET, Cote TR, Siegal JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646
60. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and effi cacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open label study. Arthritis Rheum 50:3161-3169
61. Ravirajan CT, Rahman MA, Papadaki L, Griffi ths MH, Kalsi J, Martin AC et al (1998) Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol 28:339-350, Erratum: Eur J Immunol 1999; 29: 3052
62. Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S, Takeda T et al (1993) Signifi cance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 52:14-20
63. Rahman A (2004) Autoantibodies, lupus and the science of sabotage. Rheumatology (Oxford) 43:1326-1336
64. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK (1999) Major peptide autoepitopes for nucleosome-specifi c T cells of human lupus. J Clin Invest 104:345-355
65. Kang HK, Chiang MY, Liu M, Ecklund D, Datta SK (2011) The histone peptide H471- 94 is more effective than a cocktail of peptides epitopes in controlling lupus: immunoregulatory mechanisms. J Clin Immunol 31: 379-394
66. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispin JC, Tsokos GC (2011) The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 31:769-779
67. Gigante A, Gasperini ML, Afeltra A, Barbano B, Margiotta D, Cianci R et al (2011) Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 15:15-24
68. Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syvänen AC, Rönnblom L et al (2011) Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet 7:e1002341
69. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J et al (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67:458-461
70. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775-787
71. Buckner JH (2010) Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 10:849-859
72. Yurasov SV, Wardermann H, Hammersen J, Pascual V, Meffre E, Nussenzweig MC (2004) Autoreactive B cells and immune tolerance alterations in peripheral blood of patients with systemic autoimmunity. Pediatr Res 292A
73. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S et al (2009) Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induced long term remission through de novo generation of a juvenile and tolerant immune system. Blood 113:214-223
74. Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179-204
75. Medina F, Segundo C, Campos-Caro A, González-García I, Brieva JA (2002) The heterogeneity shown by human plasma cells from tonsil, blood and bone marrow reveals graded stages of increasing maturity, but local profi les of adhesion molecule expression. Blood 99:2154-2161
76. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR et al (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165: 5970-5979
77. Anolik JH, Aringer M (2005) New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19:859-878
78. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X et al (2009) A large-scale replication study identifi es TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41:1228-1233
79. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR et al (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32:129-140
80. Bosma A, Abel-Gadir A, Isenberg DA, Jury EC, Mauri C (2012) Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 36:477-490
81. Koffl er D, Schur PH, Kunkel HG (1967) Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 126:607-624
82. Isenberg DA, Shoenfeld Y, Walport M, Mackworth-Young C, Dudeney C, Todd- Pokropek A et al (1985) Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 28:999-1007
83. Ng KP, Manson JJ, Rahman A, Isenberg DA (2006) Association of anti-nucleosome antibodies with disease fl are in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 55:900-904
84. Mannik M, Merrill CE, Stamps LD, Wener MH (2003) Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 30:1495-1504
85. Sontheimer RD, Maddison PJ, Reichlin M, Jordan RE, Stastny P, Gilliam JN (1982) Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 97:664-671
86. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT et al (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103:19854-19859
87. Quisimoro FP (2007) Other serologic abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois' Lupus erythematosus, 7th edn. Lippincott Williams and Wilkins, Philadelphia, pp 527-550
88. Pujol M, Ribera A, Vildarell M, Ordi J, Feliu E (1995) High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus. Br J Haematol 89:137-141
89. Berden JH, Licht R, van Bruggen MC, Tax WJ (1999) Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 8:299-306
90. Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P et al (2007) Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 71:664-672
91. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP (2006) Nephritogenic lupus antibodies recognize glomerular basement membrane- associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 168:1779-1792 Pedro Correia Azevedo et al.